PMID- 24710641
OWN - NLM
STAT- MEDLINE
DCOM- 20141230
LR  - 20220408
IS  - 1439-3646 (Electronic)
IS  - 0947-7349 (Linking)
VI  - 122
IP  - 5
DP  - 2014 May
TI  - Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on 
      glycemic control and cardiovascular risk factors in patients with newly diagnosed 
      uncontrolled type 2 diabetes mellitus.
PG  - 295-302
LID - 10.1055/s-0034-1370989 [doi]
AB  - OBJECTIVE: The objective of this study was to evaluate and compare the effects of 
      gliclazide-modified release (gliclazide-MR), metformine (MET) and pioglitazone 
      (PIO) monotherapies on glycemic control and conventional/non-conventional 
      cardiovascular risk factors in patients with newly diagnosed type 2 diabetes 
      mellitus (T2DM). MATERIAL AND METHODS: A single center, randomized, 52-wk 
      comparator-controlled clinical study was carried out in patients with newly 
      diagnosed uncontrolled T2DM. A total of 57 patients were randomized into 
      gliclazide-MR, metformin and pioglitazone groups. Drugs were administered for 12 
      months. Anthropometric measurements, fasting plasma glucose (FPG), postprandial 
      plasma glucose (PPG), HbA1c, insulin, HOMA-IR, lipid parameters, the markers of 
      coagulation/fibrinolysis, inflammation and endothelial dysfunction were measured 
      at baseline and at months 3, 6, and 12. RESULTS: In the gliclazide-MR group, HC, 
      FPG, HbA1c, insulin, HOMA-IR, TC, trigylcerides, Lp (a), E-selectin and Hcy were 
      significantly decreased after treatment compared to baseline. In the MET group, 
      BMI, WC, FPG, PPG, HbA1c, ICAM-1 and Hcy significantly decreased after treatment 
      compared to baseline. In PIO group, WC, HC, FPG, PPG, HbA1c, C-peptid, HOMA-IR, 
      trigylcerides, vWF, IL-6, ICAM-1, E-selectin and Hcy significantly decreased 
      after treatment compared to baseline, whereas, HDL-C increased. At the end of the 
      month 12, the decreases in insulin and HOMA-IR score were more pronounced with 
      PIO compared to gliclazide. CONCLUSIONS: Gliclazide-MR, MET and PIO 
      monotherapies, were equally effective in proving glycemic control in patients 
      with newly diagnosed, oral antidiabetic (OAD)-naive T2DM. But, improvements in 
      conventional/non-conventional cardiovascular risk factors were more pronounced in 
      patients on PIO therapy compared to gliclazide and MET therapies. Also, all of 
      the 3 drugs represent effective and safe first-line pharmacological treatment 
      options in these patients.
CI  - (c) J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart . New York.
FAU - Erem, C
AU  - Erem C
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
FAU - Ozbas, H M
AU  - Ozbas HM
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
FAU - Nuhoglu, I
AU  - Nuhoglu I
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
FAU - Deger, O
AU  - Deger O
AD  - Department of Medical Biochemistry, The Trabzon Endocrinological Studies Group, 
      Trabzon, Turkey.
FAU - Civan, N
AU  - Civan N
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
FAU - Ersoz, H O
AU  - Ersoz HO
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140407
PL  - Germany
TA  - Exp Clin Endocrinol Diabetes
JT  - Experimental and clinical endocrinology & diabetes : official journal, German 
      Society of Endocrinology [and] German Diabetes Association
JID - 9505926
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
RN  - G4PX8C4HKV (Gliclazide)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cardiovascular Diseases/*blood
MH  - *Diabetes Mellitus, Type 2/blood/drug therapy
MH  - Female
MH  - Gliclazide/*administration & dosage
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Male
MH  - Metformin/*administration & dosage
MH  - Middle Aged
MH  - Pioglitazone
MH  - Risk Factors
MH  - Thiazolidinediones/*administration & dosage
EDAT- 2014/04/09 06:00
MHDA- 2014/12/31 06:00
CRDT- 2014/04/09 06:00
PHST- 2014/04/09 06:00 [entrez]
PHST- 2014/04/09 06:00 [pubmed]
PHST- 2014/12/31 06:00 [medline]
AID - 10.1055/s-0034-1370989 [doi]
PST - ppublish
SO  - Exp Clin Endocrinol Diabetes. 2014 May;122(5):295-302. doi: 
      10.1055/s-0034-1370989. Epub 2014 Apr 7.